| Date | Title | Description |
| 21.08.2026 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Fri, Aug 21, 2026 07:30 CET Report this content
Lund, Sweden August 21, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office i... |
| 01.04.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments increases NAV by 17.2 percent and expects annual profit of CHF 272 million for the 2025/2026 financial year | HBM Healthcare Investments, an investment company specializing in the healthcare sector, successfully closed its 2025/2026 financial year as of 31 March. Over the course of the year, the net asset value (NAV) in Swiss francs increased by 17... |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding.
The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 29.09.2025 | Stocks making the biggest moves midday: CSX, Electronic Arts, Pony AI, Merus and more | - |
| 29.09.2025 | Датская Genmab покупает нидерландскую фармкомпанию Merus за $8 млрд | Genmab выкупит акции Merus по цене $97 за штуку наличными, говорится в совместном заявлении компаний в понедельник. Это примерно на 41% выше цены закрытия акций Merus, котирующихся в США, по состоянию на 26 сентября. Ранее Bloomberg News со... |
| 29.09.2025 | Genmab to Acquire HBM Portfolio Company Merus for USD 8 billion in Cash | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its listed portfolio company, Merus (Nasdaq: MRUS), has entered into a transaction agreement with Genmab (Nasdaq: GMAB). Genmab intends to acquire... |
| 28.09.2025 | S&P 500 closes higher as AI leader Nvidia rebounds, EA surges on takeover | The S&P 500 rose on Monday as Wall Street regained some of its footing after a week in which the artificial intelligence trade lost a bit of steam.
The broad market index climbed 0.26% to finish at 6,661.21, and the Nasdaq Composite adv... |
| 12.08.2024 | Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates | USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to impro... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 05.03.2024 | Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression | - |
| 03.11.2022 | Merus Announces Financial Results for the Third Quarter and Provides Business Update | – Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potenti... |
| 26.10.2022 | Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics | - MCLA-129 observed to be well tolerated with a favorable safety profile
- Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels
- Initial recommended phase 2 dose 1500 mg every two ... |
| 02.12.2021 | Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021 | UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodi... |
| 02.11.2021 | Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update | Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus presented early clinical data on MCL... |
| 30.09.2021 | Merus N : Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibod... |
| 20.12.2019 | Bill Lundberg takes over the reins at Merus; Former Akcea COO Jeffrey Goldberg takes the helm of Immunitas | Bill Lundberg
→ Dutch biotech Merus, who struck up a $200 million bispecific development deal with Incyte in 2016, is losing their CEO Ton Logtenberg. Meanwhile, the company has nominated Sven (Bill) Ante Lundberg to be Lo... |
| 16.03.2017 | Merus Named BioCapital Europe 2017 Company of the Year | Utrecht, The Netherlands — Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has been named BioCapital Europe’s Company of the Year for 2017. I... |
| 27.01.2017 | Jounce Therapeutics prices IPO beyond expectations (Updated) | The early stage biotech company, with a focus on cancer immunotherapy and targeted therapeutics, has raised $102 million in private funding to date, from investors such as Third Rock.
Jounce is listed on the NASDAQ Capital Market under the ... |
| 21.12.2016 | Incyte and Merus Announce Global Strategic Research Collaboration | Wilmington, DE and Utrecht, The Netherlands – Incyte Corporation (NASDAQ:INCY) and Merus N.V. (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and devel... |
| 15.11.2016 | Merus Announces Favorable Decisions in Europe and Japan for Patent Covering Genetically-Modified Mice | Utrecht, The Netherlands — Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it received two favorable rulings for its European patent EP 2147594 ... |
| 19.10.2016 | Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody | UTRECHT, The Netherlands — Merus N.V. (NASDAQ: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharm... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 03.05.2016 | Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating MCLA-117 in AML Patients | Utrecht, The Netherlands — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been dosed in the Company’s Phase 1/2 clinical trial evaluati... |
| 09.03.2016 | Merus Announces Issuance of Three U.S. Patents | Utrecht, The Netherlands — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents rela... |
| 04.01.2016 | Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies | Utrecht, The Netherlands and Villejuif, France — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, toda... |
| 27.08.2015 | Merus Raises €72.8M in Series C Funding | Merus B.V., an Utrecht, the Netherlands-based clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, raised up to € 72.8m ($80.5m) in Series C funding.
The first tranche of unidsclosed amount under th... |
| 26.08.2015 | Merus Enters Into € 72.8 million Series C Financing | Utrecht, The Netherlands — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to € 72.8 millio... |
| 10.08.2015 | Merus Prevails in Inequitable Conduct Case Against Regeneron | Utrecht, The Netherlands — Merus, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that it won its inequitable conduct trial against Regeneron. In a decision issued on Thursday,... |
| 01.06.2015 | Merus Appoints Mark Iwicki as President of the Supervisory Board | Utrecht, The Netherlands — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board.
“We welcome M... |
| 20.05.2015 | Merus and Selexis Receive a € 2.1 Million Eurostars Grant | Utrecht, The Netherlands — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologies for biologics drug discovery and Res... |
| 08.04.2015 | Merus Reaches Pivotal Milestone in Collaboration with ONO PHARMACEUTICAL CO., LTD. | Utrecht, The Netherlands, 8th April 2015 – Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has reached a preclinical milestone in a bispecific antibody research and license collabor... |
| 04.02.2015 | Merus Starts Phase I/II Clinical Trial for MCLA-128, an ADCC-enhanced Bispecific Antibody for Solid Tumors | Utrecht, The Netherlands — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced the initiation of a phase I/II clinical study of MCLA-128 for the treatment of solid tumo... |
| 24.04.2014 | Merus Capital secures $50m for two funds | Venture capital firm Merus Capital has secured $50m for two funds, Merus Capital II and Merus Capital Opportunity Fund. |
| 07.10.2013 | Merus BV Extends Series B Round By $42M |
UTRECHT, THE NETHERLANDS, Merus BV, a biopharma focusing on antibody therapeutics, has announced a 31 million euro ($42 million US) extension to a Series B financing round, bringing the total raised to 47.6 million euro ($65 million US).
... |
| 03.10.2013 | Merus Secures €31 Million in Series B Round Extension | - |
| 03.10.2013 | Merus Raises €31M in Series B Financing | Merus B.V., a Utrecht, The Netherlands-based biopharmaceutical company focusing on innovative human antibody therapeutics, raised an additional €31m (US$42m) in Series B financing.
This brought the total amount raised by the company in the ... |
| 24.04.2013 | Merus Capital picks up $17m towards second iEnterprise fund | Merus Capital, a venture firm formed by a trio of former Google and Microsoft executives, has gathered more than $17m as |
| 07.02.2013 | Merus Achieves Milestone with Novartis Option Fund | February 7, 2013
Utrecht, The Netherlands — Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced it has met the second milestone in its option agreement with the Novartis Option Fund (... |
| 29.01.2010 | The Netherlands, Merus Closes €21.7M Series B Financing | Merus, a Utrecht, The Netherlands-based biopharmaceutical company developing a pipeline of human therapeutic antibodies, completed its €21.7m (approximately $30.7m) Series B financing.
The round was led by new investors LSP (Life Sciences P... |
| - | Jounce Therapeutics prices IPO beyond expectations (Updated) | Jounce Therapeutics has raised $101.8 million for its initial public offering after pricing the IPO at $16 per share, according to a company news release. The price exceeded initial projections of $13 to $15 per share.
Reaffirming its new v... |
| - | Merus Audio raises 2.2 million Euro | COPENHAGEN — March 19, 2015. Merus Audio has raised EUR 2.2M in its Series B round of financing. |
